.jpg)
A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price
Studies in thousands of people on multiple continents now show the malaria drug hydroxychloroquine does not help patients hospitalized with Covid-19 live longer. But on Tuesday the White House, based on a new study that outsiders greeted with deep skepticism, disagreed.
Now the Food and Drug Administration again risks being pulled into an ugly political fracas over whether to permit more patients to be treated with the drug. It is a debate that threatens to undermine the agency’s credibility when it needs it perhaps more than ever.
